Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
Oligomer modified diaromatic substituted compounds
US9226970B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9226970-B2 |
| Application number | US-201113580580-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 22, 2011 |
| Priority date | Feb 22, 2010 |
| Publication date | Jan 5, 2016 |
| Grant date | Jan 5, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds comprising diaromatic substituted compound residues, namely the anti-viral (anti-HIV) drug delavirdine, covalently attached via a linkage to water-soluble, non-peptidic oligomers, specifically to poly(ethylene glycol) (PEG) oligomers. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified diaromatic substituted compounds.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having the following structure, wherein n is an integer between 1 and 30, inclusive, and pharmaceutical salts thereof. 2. The compound of claim 1 , wherein n is an integer between 1 and 10. 3. A composition comprising (i) a compound of claim 1 , and (ii) a pharmaceutically acceptable excipient. 4. A composition of matter comprising a compound of claim 1 present in a dosage form. 5. A compound of claim 1 , wherein n is 1. 6. A compound of claim 1 , wherein n is 2. 7. A compound of claim 1 , wherein n is 3. 8. A compound of claim 1 , wherein n is 4. 9. A compound of claim 1 , wherein n is 5. 10. A compound of claim 1 , wherein n is 6. 11. A compound of claim 1 , wherein n is 7. 12. A compound of claim 1 , wherein n is 8. 13. A compound of claim 1 , wherein n is 9. 14. A compound of claim 1 , wherein n is 10.
Assignees
Inventors
Classifications
- A61K31/496Primary
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
for HIV · CPC title
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
- A61K47/48215Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9226970B2 cover?
- Disclosed are compounds comprising diaromatic substituted compound residues, namely the anti-viral (anti-HIV) drug delavirdine, covalently attached via a linkage to water-soluble, non-peptidic oligomers, specifically to poly(ethylene glycol) (PEG) oligomers. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified…
- Who is the assignee on this patent?
- Riggs-Sauthier Jennifer, Deng Bo-Liang, Nektar Therapeutics
- What technology area does this patent fall under?
- Primary CPC classification A61K31/496. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).